Euroopan unioni - suomi - EMA (European Medicines Agency)

alfasigma s.p.a. - metyylitioniniumkloridia - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfooma, mantle-cell - antineoplastiset aineet - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Euroopan unioni - suomi - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - muut hermoston huumeet - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Euroopan unioni - suomi - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfooma, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

leo - dimenhydrinatum - tabletti - 100 mg - difenhydramiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

pharmacia limited - dimenhydrinatum - tabletti - 50 mg - difenhydramiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

leo - dimenhydrinatum,kofeiini - tabletti - difenhydramiini, yhdistelmävalmisteet